Proton Beam Radiation
ProcedureOnce a day, 5 days a week (Monday-Friday) for 3 weeks.
NCT Number: NCT00465023
The main purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects. We will also gather information to determine the ability of proton beam to destroy cancer cells in the liver. There are two types of external radiation treatments (proton beam and photon beam). Proton beam radiation is a very accurate kind of treatment that has been shown to affect less normal tissue than a regular radiation beam. The accuracy allows us to more safely increase the amount of radiation delivered to eliminate cancer and may potentially reduce the side effects normally experienced with standard radiation therapy.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Once a day, 5 days a week (Monday-Friday) for 3 weeks.
Time frame: 4 years
Time frame: 4 years
Massachusetts General Hospital
Other
Phase I Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04484636
Adenocarcinoma, Biliary Tract Diseases
Frankfurt am Main, Hesse, Germany
View Trial DetailsNCT06899152
Adenocarcinoma, Carcinoma
The Bronx, New York, United States
View Trial DetailsNCT05451043
Adenocarcinoma, Biliary Tract Cancer
Edmonton, Alberta, Canada
View Trial DetailsNCT03132792
AFP Expressing Tumors, Digestive System Diseases
Phoenix, Arizona, United States
View Trial Details